Veritas Raises $30 Million from China-Connected Investors for Genetic Tests

Veritas Genetics, a Boston-Hangzhou affordable genetics testing company, raised $30 million from China-connected investors. Veritas offers a $999 complete genomic screen, which is delivered to smart phones, plus the myBRCA and ovarian cancer non-invasive tests for cancer predisposition along with prenatal tests. The round was led by Trustbridge Partners, a Boston-Shanghai growth investor, and Jiangsu Simcere Pharma plus Lilly Asia Ventures. More details.... Share this with colleagues: // //